Statins effect on smooth muscle cell proliferation

Stefano Bellosta, Lorenzo Arnaboldi, Lorenzo Gerosa, Monica Canavesi, Rachele Parente, Roberta Baetta, Rodolfo Paoletti, Alberto Corsini

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Clinical trials have firmly established that 3-hydroxy-3-methylglutaryl- coenzyme-A reductase inhibitors (statins) can induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. These beneficial effects of statins are usually assumed to result from their ability to reduce cholesterol synthesis. However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Indeed, statins can interfere with major events involved in the formation and the evolution of atherosclerotic lesions, such as arterial myocyte migration and proliferation and cholesterol accumulation, independent of their hypolipidemic properties. The aim of this article is to focus on clinical and experimental data that show that statins possess effects beyond cholesterol lowering, particularly on arterial smooth muscle cell proliferation. The contribution of these direct vascular effects to the reduction of cardiovascular events observed in clinical trials with statins represents one of the major challenges for future studies to understand the antiatherosclerotic benefits of these agents.

Original languageEnglish
Pages (from-to)347-356
Number of pages10
JournalSeminars in Vascular Medicine
Volume4
Issue number4
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Smooth Muscle Myocytes
Cell Proliferation
Cholesterol
Blood Vessels
Oxidoreductases
Clinical Trials
Mevalonic Acid
Terpenes
Muscle Cells
Coronary Artery Disease
Atherosclerosis
Morbidity

Keywords

  • Atherosclerosis
  • Cell growth
  • HMG-CoA reductase inhibitors
  • Hypolipidemic drugs
  • Statin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bellosta, S., Arnaboldi, L., Gerosa, L., Canavesi, M., Parente, R., Baetta, R., ... Corsini, A. (2004). Statins effect on smooth muscle cell proliferation. Seminars in Vascular Medicine, 4(4), 347-356. https://doi.org/10.1055/s-2004-869591

Statins effect on smooth muscle cell proliferation. / Bellosta, Stefano; Arnaboldi, Lorenzo; Gerosa, Lorenzo; Canavesi, Monica; Parente, Rachele; Baetta, Roberta; Paoletti, Rodolfo; Corsini, Alberto.

In: Seminars in Vascular Medicine, Vol. 4, No. 4, 11.2004, p. 347-356.

Research output: Contribution to journalArticle

Bellosta, S, Arnaboldi, L, Gerosa, L, Canavesi, M, Parente, R, Baetta, R, Paoletti, R & Corsini, A 2004, 'Statins effect on smooth muscle cell proliferation', Seminars in Vascular Medicine, vol. 4, no. 4, pp. 347-356. https://doi.org/10.1055/s-2004-869591
Bellosta, Stefano ; Arnaboldi, Lorenzo ; Gerosa, Lorenzo ; Canavesi, Monica ; Parente, Rachele ; Baetta, Roberta ; Paoletti, Rodolfo ; Corsini, Alberto. / Statins effect on smooth muscle cell proliferation. In: Seminars in Vascular Medicine. 2004 ; Vol. 4, No. 4. pp. 347-356.
@article{d5109ee1858844469871b910f49cfaf0,
title = "Statins effect on smooth muscle cell proliferation",
abstract = "Clinical trials have firmly established that 3-hydroxy-3-methylglutaryl- coenzyme-A reductase inhibitors (statins) can induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. These beneficial effects of statins are usually assumed to result from their ability to reduce cholesterol synthesis. However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Indeed, statins can interfere with major events involved in the formation and the evolution of atherosclerotic lesions, such as arterial myocyte migration and proliferation and cholesterol accumulation, independent of their hypolipidemic properties. The aim of this article is to focus on clinical and experimental data that show that statins possess effects beyond cholesterol lowering, particularly on arterial smooth muscle cell proliferation. The contribution of these direct vascular effects to the reduction of cardiovascular events observed in clinical trials with statins represents one of the major challenges for future studies to understand the antiatherosclerotic benefits of these agents.",
keywords = "Atherosclerosis, Cell growth, HMG-CoA reductase inhibitors, Hypolipidemic drugs, Statin",
author = "Stefano Bellosta and Lorenzo Arnaboldi and Lorenzo Gerosa and Monica Canavesi and Rachele Parente and Roberta Baetta and Rodolfo Paoletti and Alberto Corsini",
year = "2004",
month = "11",
doi = "10.1055/s-2004-869591",
language = "English",
volume = "4",
pages = "347--356",
journal = "Seminars in Vascular Medicine",
issn = "1528-9648",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Statins effect on smooth muscle cell proliferation

AU - Bellosta, Stefano

AU - Arnaboldi, Lorenzo

AU - Gerosa, Lorenzo

AU - Canavesi, Monica

AU - Parente, Rachele

AU - Baetta, Roberta

AU - Paoletti, Rodolfo

AU - Corsini, Alberto

PY - 2004/11

Y1 - 2004/11

N2 - Clinical trials have firmly established that 3-hydroxy-3-methylglutaryl- coenzyme-A reductase inhibitors (statins) can induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. These beneficial effects of statins are usually assumed to result from their ability to reduce cholesterol synthesis. However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Indeed, statins can interfere with major events involved in the formation and the evolution of atherosclerotic lesions, such as arterial myocyte migration and proliferation and cholesterol accumulation, independent of their hypolipidemic properties. The aim of this article is to focus on clinical and experimental data that show that statins possess effects beyond cholesterol lowering, particularly on arterial smooth muscle cell proliferation. The contribution of these direct vascular effects to the reduction of cardiovascular events observed in clinical trials with statins represents one of the major challenges for future studies to understand the antiatherosclerotic benefits of these agents.

AB - Clinical trials have firmly established that 3-hydroxy-3-methylglutaryl- coenzyme-A reductase inhibitors (statins) can induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. These beneficial effects of statins are usually assumed to result from their ability to reduce cholesterol synthesis. However, because mevalonic acid is the precursor not only of cholesterol but also of many nonsteroidal isoprenoid compounds, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may result in pleiotropic effects. Indeed, statins can interfere with major events involved in the formation and the evolution of atherosclerotic lesions, such as arterial myocyte migration and proliferation and cholesterol accumulation, independent of their hypolipidemic properties. The aim of this article is to focus on clinical and experimental data that show that statins possess effects beyond cholesterol lowering, particularly on arterial smooth muscle cell proliferation. The contribution of these direct vascular effects to the reduction of cardiovascular events observed in clinical trials with statins represents one of the major challenges for future studies to understand the antiatherosclerotic benefits of these agents.

KW - Atherosclerosis

KW - Cell growth

KW - HMG-CoA reductase inhibitors

KW - Hypolipidemic drugs

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=17744365182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744365182&partnerID=8YFLogxK

U2 - 10.1055/s-2004-869591

DO - 10.1055/s-2004-869591

M3 - Article

C2 - 15861311

AN - SCOPUS:17744365182

VL - 4

SP - 347

EP - 356

JO - Seminars in Vascular Medicine

JF - Seminars in Vascular Medicine

SN - 1528-9648

IS - 4

ER -